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Abstract 
Purpose: The aim of this volumetric study was to evaluate the relationship between brain atrophy quantification in 
multiple sclerosis (MS) patients and the progression of disability measured by neurological standardised tests. 
Material and methods: Seventeen patients (mean age 40.89 years) with clinically definite MS and 24 control subjects 
(mean age 38.45 years) were enrolled in the study. Brain examinations were performed on a 1.5T MR scanner. Auto-
matic brain segmentation was done using FreeSurfer. Neurological disability was assessed in all patients in baseline 
and after a median follow-up of two years, using EDSS score evaluation.
Results: In MS patients we found significantly (p < 0.05) higher atrophy rates in many brain areas compared with the 
control group. The white matter did not show any significant rate of volume loss in MS patients compared to healthy 
controls. Significant changes were found only in grey matter volume in MS subjects. At the follow-up evaluation after 
two years MS patients with deterioration in disability revealed significantly decreased cerebral volume in 14 grey 
matter areas at baseline magnetic resonance imaging (MRI) compared to MS subjects without disability progression.
Conclusions: Grey matter atrophy is associated with the degree of disability in MS patients. Our results suggest that 
morphometric measurements of brain volume could be a promising non-invasive biomarker in assessing the volu-
metric changes in MS patients as related to disability progression in the course of the disease.
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Introduction
Magnetic resonance imaging (MRI) is the method of 
choice in the diagnosis of multiple sclerosis (MS) as well 
as in monitoring the disease’s activity [1]. In recent years 
many researchers have paid much attention to the cor-
relation between radiological findings and clinical state 
of the patients [2]. 
In MS the lesion volume reflects the inflammatory fea-
ture of the disease, while atrophy measures the quantitative-
ly neurodegenerative aspect of the disease, which play an 
important role in all disease stages. The issue of brain atro-
phy in MS patients is not sufficiently reported in the litera-
ture with regards to the nature of their clinical significance. 
A number of studies suggest the role of brain atrophy mea-
sures in the prediction of MS progression [1,3,4] (Figure 1). 
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In our previous review we described the mechanisms 
that contribute to brain atrophy and important biological 
factors that can influence the accuracy of brain volume 
quantification [5]. Atrophy is not only seen within the le-
sions but also in normal-appearing white matter and grey 
matter. Brain atrophy is one of the most important indica-
tors of neurodegeneration and clinical disease progression 
in MS patients and reflects both inflammation- induced 
axonal loss and post-inflammatory neurodegeneration.
However, longitudinal changes of brain volume and 
their correlations with clinical worsening in MS have still 
not been adequately investigated.
In our study we evaluated the relationship between the 
degree of disability in the course of MS and volumetric 
brain abnormalities. The primary purpose of this study 
was to show MRI volumetric features associated with MS. 
The secondary aim was to compare the results from brain 
tissue segmentations with clinical parameters assessing 
the degree of disability using the Expanded Disability 
Status Scale (EDSS).
Material and methods
Study population 
Seventeen patients diagnosed with MS according to 
the revised McDonald criteria (mean age 52 years, range 
34-70 years). Patients were recruited from the Depart-
ment of Neurology at Wroclaw Medical University be-
tween 2014 and 2016. The main demographic and clinical 
characteristics of the patients are shown in Table 1.
The inclusion criteria for MS patients were: established 
diagnosis of MS according to 2010 McDonald Criteria, 
established diagnosis of relapsing remitting multiple scle-
rosis (RRMS) and disease duration 1-5 years. 
Exclusion criteria were concomitant disorders (cere-
brovascular disease, neurodegenerative disorder): positive 
history of alcohol abuse, psychiatric or psychological dis-
orders, and steroid or psychoactive drug treatment in the 
three months preceding entry to the study.
Control group
Twenty-four healthy volunteer subjects (11 males, 
13 females), age range between 32 and 68 years (mean age 
48 years), with no history of neurological or psychiatric 
disorders were included as the control group. The inclusion 
criterion was normal conventional brain MR imaging. 
A total of healthy controls were matched to the MS pa-
tients regarding age, sex, and educational level, as shown 
in Table 1. 
The study protocol was approved by the Wrocław Uni-
versity Ethics Committee. All the procedures performed 
in the studies involving human participants were in accor-
dance with the ethical standards of the institutional and/
or national research committee and with the 1964 Hel-
sinki declaration and its later amendments or comparable 
ethical standards. Informed consent was obtained from all 
individual participants included in the study.
MR imaging protocols and voxel-based morphometric 
assessment 
Magnetic resonance imaging (MRI) of the cerebrum, 
cerebellum, and brain stem was performed in 17 individ-
uals with clinically definite multiple sclerosis (MS) and in 
24 control subjects. MRI examination was performed on 
a 1.5 Tesla scanner (Signa Hdx, GE Medical Systems) using 
a 16-channel head coil. Imaging was done in the coronal, 
axial, and sagittal planes. Data were transferred to a GE Ad-
vantage Workstation and post-processed using fully-auto-
mated software Freesurfer image analysis suite version 
6.0. On the basis of the volumetric Bravo sequence, brain 
segmentation was performed. The total brain volume and 
volume of each region was computed using an interactive 
image analysis system. A stereotactic atlas was used as a ref-
erence for segmenting brain structures.
Table 1. Demographic and clinical characteristics of multiple sclerosis (MS) 
patients and healthy controls (CG) 
Factor MS CG
Sex, M/F 5/12 11/13
Age, years:
Mean 52 48
Range 34-70 32-68
MS estimated duration (years) 1-5 NA
Type of therapy
Interferon beta-1b 11 NA
Glatiramer acetate 1 NA
Fingolimod 3 NA
Natalizumab 1 NA
Betaferon 1 NA
Figure 1. Components of tissue elements contributing to brain volume loss 
due to multiple sclerosis pathology
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Bravo is one of the basic acquisition protocols for 
Automated Brain Segmentation, as we described in our 
previous paper [6]. The technical parameters of Bravo 
sequence are as follows: Acquisition time: 5:15 Voxel size: 
1.0 × 1.0 × 1.0 mm3, Geometry: FoV 25.6 cm (256 × 256 
matrix), 176 sagittal slices, and slice thickness 1 mm. 
High-resolution, three-dimensional (3D) sequences are 
preferred for measurement of brain volume because they 
provide excellent T1w contrast between grey and white 
matter and are good for showing anatomical details. 
Neurological assessment 
All patients had a full neurological examination at the 
time the MRI scans were performed and after a two-year 
follow-up. The disability assessment was performed using 
the EDSS (Kurtzke 1983) scale to evaluate the intellectu-
al and functional impairments of MS. The occurrence of 
clinical multiple sclerosis relapses during the study period 
was also assessed.
Patients were observed neurologically by the same neu-
rologist, who was unaware of the MRI results. At follow-up 
evaluations, patients were considered clinically worsened 
if they had an EDSS score increase of > 0.5 compared to 
the baseline. 
EDSS is the most widely-used measure for assessing 
the degree of neurological impairment in MS within eight 
functional systems:
• pyramidal – weakness or difficulty moving limbs,
• cerebellar – ataxia, loss of coordination or tremor,
• brainstem – problems with speech, swallowing, and nys-
tagmus,
• sensory – numbness or loss of sensations,
• bowel and bladder function,
• visual function,
• cerebral (or mental) functions,
• ambulation.
The total score of EDSS ranges from 0 to 10.
At the end of the study we decided to classify the pa-
tients according to their cognitive status as follows:
(a) disability regression—patients who presented at least 0.5 
improvement from the baseline status in the EDSS test,
(b) disability progression—worsening required at least 0.5 
decreased EDSS score from the baseline status,
(c) stable patients—patients not meeting the above-men-
tioned criteria were classified as stable. 
The relationship between atrophy measures and clini-
cal signs was investigated.
All procedures performed in studies involving human 
participants were in accordance with the ethical standards 
of Wroclaw Medical University.
Statistical analysis
Statistical analyses were performed to determine asso-
ciations between volumetric parameters and the degree of 
disability measured by EDSS for the MS group. Continu-
ous variables were expressed as mean ± standard devia-
tion in the case of normal distribution and median with 
interquartile range for non-normal distribution. Normali-
ty of distribution was verified using the Shapiro-Wilk 
W test. For variables with normal distribution, the ANOVA 
and Turkey post-hoc tests with correction for non-equal 
number of cases were used to evaluate differences between 
the examined groups. The non-parametric Kruskal-Wallis 
test was used to compare non-normal variables. P values 
< 0.05 were considered as statistically significant. The 
median and range of values were reported. STATISTICA 
software 13.0 (StatSoft) was used for this purpose.
Results
Neurological assessment
Mean EDSS score at baseline was 3.029 (range 1.0-6.0). 
At the end of the follow-up period we found significant dete-
rioration from baseline data for disability (mean EDSS 3.34, 
range 1.0-7.0). Overall, seven patients (41.1%) were judged 
as cognitively worsened (MS1 group – patients with deteri-
oration) at the end of the follow-up, and 10 subjects (58.9%) 
remained stable (MS0 group – patients without deteriora-
tion). There were no patients who showed improvement. 
MRI and brain volume changes
Whole brain volume measurement has been estab-
lished as a robust measure to differentiate the level of at-
rophy in MS patients, compared to age- and sex-matched 
healthy individuals. Compared with healthy controls, MS 
patients during the follow-up period displayed significant 
decrease in brain parenchymal volumes in several areas 
within grey matter. Regions of significant brain parenchy-
mal volume changes are presented in Table 2.
Figures 2, 3, and 4 present a comparison of volumes of 
selected cerebral areas in particular groups.
The white matter did not show a significant rate of 
volume loss in MS patients compared to healthy controls. 
When we compared the rate of volume loss across dif-
ferent regions in all MS patients together, compared with 
CG, the greater decline was observed in the four grey mat-
ter regions – Table 2.  
Comparison of the MS0 (patients without deterioration) 
and CG groups
Compared with the healthy control group, MS patients 
without progression showed significantly higher volume 
loss within the following four areas: left straight gyrus 
(gyrus rectus) (p = 0.021), left planum polare of the superior 
temporal gyrus (p = 0.028), horizontal ramus of the lateral 
sulcus (p = 0.030), and left Broca’s area (pars triangularis) 
(p = 0.097).
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Figure 2. The horizontal ramus of the lateral sulcus volume in individual 
groups. MS1 –patients with progression, MS0- patients without progres-
sion, CG –control group
Figure 3. Right  anterior part of the cingulate gyrus volume in individual 
groups. MS1 – patients with progression, MS0 – patients without progres-
sion, CG – control group
Figure 4. Lateral orbitofrontal cortex volume in individual groups. MS1 – patients 
with progression, MS0 – patients without progression, CG – control group
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Comparison of the MS1 (patients with deterioration) 
and CG groups
Significantly higher volume loss in MS patients with 
progression compared with healthy controls was observed 
within 14 grey matter areas (Table 3). 
Comparison of the MS1 (patients with deterioration) 
and MS0 groups (patients without deterioration)
Significantly higher volume loss was found in MS 
patients with progression compared to those with stable 
disease in several areas (Table 3).
Discussion
Multiple sclerosis is a chronic autoimmune disease 
that causes neurological problems and results in progres-
sive disability. 
Multiple sclerosis-related brain atrophy is a conse-
quence of both underlying pathology (neuroinflammation) 
and neuroaxonal loss. Brain volume loss in MS patients oc-
curs at a faster rate than in the healthy population: 0.5-1.0% 
vs. 0.1-0.3% per year [7,8]. Atrophy may be found early in 
the disease course even before clinical symptoms and lead 
to long-term neurological disability [9,10].
Magnetic resonance imaging (MRI) is an important 
tool not only in the process of diagnosis but also in the 
monitoring of disease activity and predicting treatment 
efficacy [11]. In the literature there is still inconsistency 
regarding MRI protocols and the frequency of neurological 
examinations. 
The primary objective of this study was to evaluate the 
correlation between MR-based quantitative brain volume 
changes and clinical deterioration in the course of MS [12]. 
There are several freely available tools for automated 
brain volumetry that are commonly used in MS patients. 
In our study we chose one of the most popular software 
packages – FreeSurfer [13-16]. These automated techniques 
express the results as a percentage of the change in brain 
volume.
Until now, EDSS has been a widely-accepted measure 
of clinical disability in MS patients and can provide useful 
information about the clinical state of the patients. 
There are several limitations when using EDSS alone 
as an outcome measure. First of all it is based on neuro-
logical examination, which is inherently subjective [17]. 
Furthermore, the number of relapses strongly depends on 
the frequency of medical visits during the trial duration 
[18,19]. These factors may confound the interpretation of 
relapse rate reduction in treatment trials. Also, the clinical 
state of the patient does not reflect the true activity of MS 
in the central nervous system [20]. These factors poten-
tially limit the use of EDSS as a separate measure.  
Our study demonstrated that a remarkable part of the 
study population had worsening disability (41%). These 
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correlations existed throughout the disease course and in 
all clinical phenotypes.
The white matter did not show a significant rate of vol-
ume loss in MS patients and healthy controls. Our results 
are consistent with other reports [8] indicating that rela-
tionships between whole brain atrophy and clinical changes 
are weak or absent. Overall cognitive impairment did not 
correlate significantly with age, disease duration, and type 
of treatment.
The more detailed post-hoc analyses showed the fol-
lowing baseline grey matter volumes: right somatosen-
sory area (p = 0.000538), paracentral lobule (p = 0.007), 
right short insular gyri (p = 0.007), and left Broca’s area 
(pars triangularis) (p = 0.003) were associated with future 
Table 3. Mean volumes of certain brain structures in different groups: multiple sclerosis group without neurological deterioration (MS0), with neurological 
progression (MS1), and control group (CG). Turkey test with correction for non-equal groups. *Kruskall Wallis test
Brain region p
Mean MS0 Mean MS1 Mean CG MS0 vs. CG MS1 vs. CG MS1 vs. MS0
Left straight gyrus (gyrus rectus) 2028.6 2152.4 2376.7 0.0212 0.2974 0.6800
Left planum polare of the superior temporal gyrus 1233.3 1097.8 1529.1 0.0283 0.0061 0.5631
Left horizontal ramus of the lateral sulcus 390.5 336.0 460.2 0.0301 0.2122 0.5062
Left calcarine volume 2546.5 2319.8 3033.4 0.0801 0.0273 0.6693
Left medial occipitotemporal sulcus and lingual sulcus 2731.3 2119.8 3082.9 0.2120 0.0013 0.0448
Left MT volume 2703.6 2234.8 3020.6 0.0790 0.0004 0.0248
Right anterior part of the cingulate gyrus 2536.3 2141.8 2839.8 0.1281 0.0011 0.0904
Right cuneus 2566.1 2134.8 2782.5 0.4692 0.0150 0.1325
Right short insular gyri 1558.7 1289.7 1742.5 0.2720 0.0072 0.1477
Right lateral orbital sulcus* 491.0 567.0 648.5 1.0000 0.2130 0.0069
Right somatosensory area* 2366.0 2125.0 2410.0 0.0674 0.0005 0.5930
Left Broca’s area (pars triangularis) 6958.2 5776.2 8099.2 0.0973 0.0030 0.1680
Right orbital part of inferior frontal gyrus 2316.1 2029.7 2602.8 0.1824 0.0120 0.2990
Right posterior cingulate cortex 2728.8 2591.1 3123.0 0.8142 0.0500 0.1037
Left lateral orbitofrontal cortex 6441.8 5844.8 7210.8 0.2691 0.0031 0.0521
Left paracentral lobule 3006.5 2630.2 3410.2 0.2751 0.0072 0.1262
Left opercular part of inferior frontal gyrus* 3779.0 3455.0 4430.0 0.5330 0.0008 0.0531
Left posterior cingulate cortex 2711.8 2462.4 2977.1 0.4635 0.0470 0.2934
Left insula cortex* 5769.5 6018.0 6195.0 1.0000 0.2940 0.0050
Location Mean volume p values*
MS CG MS/CG
Left Broca’s area (pars triangularis) 3776.4 4223.8 0.0062
Right somatosensory area 2307.5 2482.5 0.0423
Right Broca’s area (pars opercularis) 7171.5 8099.2 0.0197
Right primary motor area (anterior) 2761.0 3112.9 0.0122
Right superior temporal sulcus (parallel sulcus) – grey matter volume 7911.2 8948.00 0.0404
Right lateral orbital sulcus – grey matter volume 489.0 621.2 0.0035
Left insula cortex – grey matter volume 5968.4 6404.5 0.0499
Left lateral division of orbitofrontal cortex – grey matter volume 2866.1 3237.5 0.0177
Right orbital gyri – grey matter volume 5786.8 6261.7 0.0373
Left orbital gyri – grey matter volume 5336.1 5807.1 0.0475
*p < 0.05 was set as statistically significant
Table 2. Mean volumes of certain brain structures in the whole multiple sclerosis group (MS) and control group (CG)
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EDSS progression. Our findings suggest that volume loss 
of these regions might become biomarkers of clinical dis-
ability progression. From all of them the right somatosen-
sory area volume had the highest predictive value of EDSS 
progression during follow-up (p = 0.000538).
The primary somatosensory cortex is located in the 
postcentral gyrus in the parietal lobe and is responsible 
for processing somatic sensations – detecting touch, pro-
prioception, and temperature. The somatosensory cortex 
receives all sensory input from the opposite side of the 
body. The damage in this area results in ignorance of cer-
tain body regions or even agnosia. On the basis of the 
above results, we put forward a hypothesis that impair-
ments in somatosensory function may be the most sen-
sible to atrophy and become an indicator of neurological 
impairment in multiple sclerosis. 
These differences in mean volume values should be re-
garded as not significant, due to the small size of the groups 
and low power calculations: about 0.5 for t-tests for depen-
dent variables (comparisons before and after treatment) 
and about 0.25 for independent variables (comparisons 
with the control group). We therefore plan to repeat the 
measurements on the same scanner and on a larger cohort 
of patients to confirm our preliminary results.   
The recent findings support the importance of the ear-
ly use of disease modifying therapy in clinically asymp-
tomatic patients without remarkable physical disability. 
Clinical assessment can be improved by using EDSS in 
conjunction with MRI measures. Furthermore, the quan-
tification of atrophy rate may become a useful outcome 
measure in neuroprotective clinical trials.
The importance of measuring brain atrophy in the 
course of MS is widely raised in the literature. Zivadin-
ov et al. investigated the association between cortical and 
subcortical volume changes and disability progression 
[21]. After five years of follow-up, patients with sustained 
disability progression (SDP) had significantly greater per-
centage of atrophy rates compared with those without SDP 
in the whole brain volume (p < 0.0001), cortex (p = 0.001), 
total grey matter (p = 0.003), and thalamus (p = 0.01). 
The same author reported also that thalamic atrophy and 
increase in lateral ventricle volumes in clinically isolated 
syndrome (CIS) is associated with an increased risk of con-
version to MS [22]. 
In our previously published review we analysed the 
then current available evidence regarding the role of brain 
atrophy measurements and its consequence in MS patients 
[23]. Grey matter atrophy develops faster than white matter 
atrophy and correlates with physical and cognitive disability. 
Calabrese et al., in their study, suggested an associa-
tion between cortical and deep grey matter atrophy and 
the development of fatigue in relapsing-remitting multiple 
sclerosis. A significant atrophy of striatum, thalamus, su-
perior frontal gyrus, and inferior parietal gyrus was ob-
served in fatigued patients compared with non-fatigued 
patients [24].
Similar findings were observed by Batista et al. [25], 
who reported a slower information-processing speed 
measured by the Paced Auditory Serial Addition Test 
(PASAT) and the Symbol Digit Modalities Test (SDMT) 
in those with greater atrophy of subcortical structures in-
cluding the thalamus and the caudate.
Our study was not designed to assess the effect of 
treatment on atrophy rates; nevertheless, all the patients 
were receiving disease modifying treatments during the 
entire study period. The majority (82%) of patients were 
receiving interferon or fingolimod. 
Therefore we are not certain whether the treatment 
administration influences the accuracy of brain atrophy 
quantification, although in the literature we found many 
reports confirming that the rates of atrophy in all clini-
cal phenotypes were similar in people who were receiv-
ing disease-modifying treatments to those who were not 
[8,26]. We suppose that drug effects are unlikely to be 
confounders of our analysis.
The quantitative magnetic resonance-based techniques 
are potentially valuable outcome measures in MS. In the 
last decade there have been a number of reports consider-
ing brain atrophy as an important endpoint for determin-
ing future progression of physical and cognitive disability 
and for assessing the efficacy of disease-modifying treat-
ment [27-29]. Such innovative techniques are potentially 
valuable. They allow multiple or continuous assessment, 
which might give a more adequate picture of a patient’s 
disability and the impact of the disease on daily life .
However, the assessment of brain atrophy is still not 
included in the standard clinical monitoring of MS pa-
tients. Identification of progression or neurodegenerative 
changes remains very challenging. There is an increasing 
need to define simple, accurate, and reproducible brain 
volume measures that can be used in clinical routine. 
The main strength of our report is the use of a quanti-
tative assessment of MRI and its correlation with clinical 
parameters, which provides additional insight into disease 
activity in MS. 
Our study also has some limitations, mainly concern-
ing the small number of patients. There is a fear that such 
a sample size might be too small to ensure adequate power. 
Nevertheless, this study is a preliminary study with a rela-
tively small sample size and short follow-up period, and we 
plan to continue our research.
All the examinations were performed by the same expe-
rienced neurologist specialising in multiple sclerosis, who 
was unaware of the MRI results. The same tests were used 
at the baseline and at the end of the two years of follow-up. 
We have provided robust measures of the whole brain vol-
ume. All patients underwent the same protocol and on the 
same MRI scanner over time. 
What is of interest is that the volumetric parameters 
were measured once. Considering that atrophy accumu-
lates slowly over time, longer follow-up is needed to detect 
significant changes. Secondly, anti-inflammatory therapies 
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may cause a decrease in brain volume due to the reso-
lution of inflammation and oedema and should not be 
regarded as true neurodegeneration. This effect, called 
pseudoatrophy, may last up to one year after initiation of 
treatment [30-32].
Therefore, further studies with larger sample sizes and 
longer follow-up at two different time points are warrant-
ed to confirm our results.
While there is a need to translate measurement of brain 
atrophy to clinical routine at the individual patient level, 
there are still a number of challenges that must be overcome, 
including biological confounding factors such as ageing, 
dehydration, and menstrual cycle. Brain volume changes 
in MS are the result of volume-gaining and volume-losing 
processes – neuroinflammation, neurodegeneration, and re-
myelination. Nevertheless, we strongly highlight the opinion 
that MRI-based volumetry should commonly be used in ev-
eryday clinical practice because it provides comprehensive 
characteristics of a patient’s clinical status. 
Conclusions
In conclusion, our results indicate that the loss of grey 
matter in multiple sclerosis could be one of the essential 
factors responsible for progression of physical disability 
and cognitive deterioration in the course of the disease. 
The use of the EDSS score, together with MRI volumetric 
measures, ensures a reliable correlation between radiolog-
ical appearance and clinical state and provides the best 
characteristic of functional impairments in MS. MRI-
based volumetry could be an attractive non-invasive neu-
roimaging biomarker in the prediction of future disability 
progression. Therefore, it should be used inseparably in 
a clinical routine in order to identify patients at the high-
est risk of disease progression as soon as possible. 
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